Inhibitor Therapeutics INTI
OTC INTI
$0.11 +0.00 (+0.00%)
At close: Oct 19, 2026 · 4:00 PM EDT

Inhibitor Therapeutics (INTI) EV to CFO (2022 - 2023)

Updated

Inhibitor Therapeutics' EV to CFO came in at -0.09 for Q3 2023.

Analysis

Inhibitor Therapeutics (INTI) EV to CFO (2022 - 2023) Analysis & Trends

Over the trailing twelve months to Sep 30, 2023, Inhibitor Therapeutics reported EV to CFO of -3.41; for FY2022, it came in at 2.10.

  • The five-year range for quarterly EV to CFO is -0.31 (Q2 2023) to 2.10 (Q4 2022).
  • Business Quant data shows INTI's EV to CFO at -0.31 (Q2 2023), -0.04 (Q1 2023) and 2.10 (Q4 2022) in the three quarters before Q3 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Inhibitor Therapeutics 19.12 Mn 11.93 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 -0.09
Jun 30, 2023 -0.31
Mar 31, 2023 -0.04
Dec 31, 2022 2.10
API Access

Inhibitor Therapeutics EV to CFO API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=INTI&period=max&api_key=YOUR_API_KEY